1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Alimera, pSivida win FDA nod for Iluvien, finally

 
• By Donna Young

Shares of Alimera and pSivida continued to rise in premarket trading on 29 September after jumping in after-hours trading on 26 September when they revealed the FDA had finally granted its approval to Iluvien (fluocinolone acetonide intravitreal implant) as a treatment for diabetic macular edema (DME) in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

Shares of Alimera and pSivida continued to rise in premarket trading on 29 September after jumping in after-hours trading on 26 September when they revealed the FDA had finally granted its approval to Iluvien (fluocinolone acetonide intravitreal implant) as a treatment for diabetic macular edema (DME) in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

J&J Dreams Of ICONIC Status For Icotrokinra

 
• By Kevin Grogan

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal

 
• By Lisa Takagi

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

More from Therapy Areas

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.